Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 6, pp 1201–1210 | Cite as

Clinical impact of an interdisciplinary patient safety program for managing drug-related problems in a long-term care hospital

  • Oreto Ruiz-Millo
  • Mónica Climente-Martí
  • Ana María Galbis-Bernácer
  • José Ramón Navarro-Sanz
Research Article

Abstract

Background Medication reviews intended to identify drug-related problems (DRPs) have been researched in primary care, acute care and nursing homes rather than in long-term care hospitals (LTCHs). Objectives To assess the clinical impact of an interdisciplinary pharmacotherapy quality improvement and patient safety program in elderly patients with polypharmacy admitted to an LTCH. Setting An interventional, longitudinal, prospective study was conducted in a Spanish LTCH Method A total of 162 elderly (≥ 70 years) patients with polypharmacy (≥ 5 medications) were included. Pharmacist conducted the pharmacotherapy follow-up of patients (reconciliation, pharmacotherapeutic optimization, educational interviews) from admission to discharge. Demographic, clinical and treatment-related variables were recorded. Main outcome measured Clinical impact of the program by DRP-based effectiveness and drug-related morbidity (DRM)-based safety indicators. Results 895 DRPs (median of 5 (1–23)) were identified in 153 (94.4%) patients. The most common DRPs were unnecessary drug (25.3%), dosage too high (24.9%) and a need for additional drug (24.8%). The most frequent pharmacotherapy recommendations were individualizing the dosage regimen (29.6%) and stopping (27.3%) or starting (21.9%) a drug. The mean implementation rate of pharmacotherapy recommendations was 90.9%. The effectiveness indicator revealed a 94.9% of prevented or resolved DRPs. The safety indicator showed an 89.3% of prevented or resolved DRM. Therefore, the program prevented or resolved 92.5% of adverse effects and 91.7% of suboptimal responses or therapeutic failures. Conclusion This interdisciplinary patient safety program seems to be a valuable approach to identify, prevent and resolve the high number of DRPs and potential DRM that elderly patients with polypharmacy admitted to an LTCH present.

Keywords

Drug-related problem Elderly Interdisciplinary care Long-term care Pharmacotherapy Quality improvement Patient safety Spain 

Notes

Acknowledgements

The authors would like to thank MD PhD Jose Luis Górriz for his suggestions for the preparation of the manuscript.

Funding

None.

Conflicts of interest

The authors have no conflicts of interest to declare.

Supplementary material

11096_2017_548_MOESM1_ESM.doc (40 kb)
Supplementary material 1 (DOC 40 kb)

References

  1. 1.
    The European Commission series. The 2015 Ageing Report: Underlying Assumptions and Projection Methodologies. European Commission. 2014. http://ec.europa.eu/economy_finance/publications/european_economy/2014/pdf/ee8_en.pdf. Accessed 23 Sept 2017.
  2. 2.
    Rechel B, Grundy E, Robine J, Cylus J, Mackenbach J, Knai C, McKee M. Ageing in the European union. Lancet. 2013;381(9874):1312–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Hanlon JT, Lindblad CI, Gray SL. Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults? Am J Geriatr Pharmacother. 2004;2(1):3–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Halvorsen KH, Ruths S, Granas AG, Viktil KK. Multidisciplinary intervention to identify and resolve drug-related problems in Norwegian nursing homes. Scand J Prim Health Care. 2010;28(2):82–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lenssen R, Heidenreich A, Schulz JB, Trautwein C, Fitzner C, Jaehde U, et al. Analysis of drug-related problems in three departments of a German University hospital. Int J Clin Pharm. 2016;38(1):119–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Tripathi S, Crabtree HM, Fryer KR, Graner KK, Arteaga GM. Impact of clinical pharmacist on the pediatric intensive care practice: an 11-year tertiary center experience. J Pediatr Pharmacol Ther. 2015;20(4):290–8.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicol. 2008;102(3):275–80.CrossRefPubMedGoogle Scholar
  8. 8.
    Nazir A, Unroe K, Tegeler M, Khan B, Azar J, Boustani M. Systematic review of interdisciplinary interventions in nursing homes. J Am Med Dir Assoc. 2013;14(7):471–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Bernsten C, Bjorkman I, Caramona M, Crealey G, Frokjaer B, Grundberger E, Pharmaceutical care of the Elderly in Europe Research (PEER) Group, et al. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven European countries. Drugs Aging. 2001;18(1):63–77.CrossRefPubMedGoogle Scholar
  10. 10.
    Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf. 2007;6(6):695–704.CrossRefPubMedGoogle Scholar
  11. 11.
    Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12(4):280–5.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Suggett E, Marriott J. Risk factors associated with the requirement for pharmaceutical intervention in the hospital setting: a systematic review of the literature. Drugs Real World Outcomes. 2016;3(3):241–63.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pharmaceutical Care Network Europe (PCNE) Foundation. The PCNE classification for drug related problems V 8.01. PCNE Foundation. 2017. http://www.pcne.org/upload/files/215_PCNE_classification_V8-01.pdf. Accessed 23 Sept 2017.
  14. 14.
    Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician’s guide. 3rd ed. New York: The McGraw-Hill Companies, Inc; 2004.Google Scholar
  15. 15.
    Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (screening tool of older person’s prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.CrossRefPubMedGoogle Scholar
  16. 16.
    By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.CrossRefGoogle Scholar
  17. 17.
    Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31–32):543–51.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Kuhn-Thiel AM, Weiss C, Wehling M. FORTA authors/expert panel members. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31(2):131–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al.. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.CrossRefPubMedGoogle Scholar
  20. 20.
    Climente Martí M, Jiménez Torres N. Manual for pharmaceutical care. 3rd ed. Valencia: AFAHPE. Dr. Peset University Hospital; 2005.Google Scholar
  21. 21.
    Shelton PS, Fritsch MA, Scott MA. Assessing medication appropriateness in the elderly: a review of available measures. Drugs Aging. 2000;16(6):437–50.CrossRefPubMedGoogle Scholar
  22. 22.
    National Transitions of Care Coalition. Improving transitions of care. The vision of the National Transitions of Care Coalition. 2008. http://www.ntocc.org/Portals/0/PDF/Resources/PolicyPaper.pdf. Accessed 23 Sept 2017.
  23. 23.
    American Pharmacists Association, American Society of Health-System Pharmacists. Improving care transitions: optimizing medication reconciliation. 2012. https://www.pharmacist.com/sites/default/files/files/2012_improving_care_transitions.pdf. Accessed 23 Sept 2017.
  24. 24.
    Petrovic M, Somers A, Onder G. Optimization of geriatric pharmacotherapy: role of multifaceted cooperation in the hospital setting. Drugs Aging. 2016;33(3):179–88.CrossRefPubMedGoogle Scholar
  25. 25.
    Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP. 1990;24(11):1093–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Modig S, Holmdahl L, Bondesson A. Medication reviews in primary care in Sweden: importance of clinical pharmacists’ recommendations on drug-related problems. Int J Clin Pharm. 2016;38(1):41–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Messerli M, Blozik E, Vriends N, Hersberger KE. Impact of a community pharmacist-led medication review on medicines use in patients on polypharmacy—a prospective randomised controlled trial. BMC Health Serv Res. 2016;16:145-016-1384-8.CrossRefGoogle Scholar
  28. 28.
    Chau SH, Jansen AP, van de Ven PM, Hoogland P, Elders PJ, Hugtenburg JG. Clinical medication reviews in elderly patients with polypharmacy: a cross-sectional study on drug-related problems in the Netherlands. Int J Clin Pharm. 2016;38(1):46–53.CrossRefPubMedGoogle Scholar
  29. 29.
    O’Connell MB, Chang F, Tocco A, Mills ME, Hwang JM, Garwood CL, et al. Drug-related-problem outcomes and program satisfaction from a comprehensive brown bag medication review. J Am Geriatr Soc. 2015;63(9):1900–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhai XB, Gu ZC, Liu XY. Effectiveness of the clinical pharmacist in reducing mortality in hospitalized cardiac patients: a propensity score-matched analysis. Ther Clin Risk Manag. 2016;12:241–50.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ruths S, Straand J, Nygaard HA. Multidisciplinary medication review in nursing home residents: what are the most significant drug-related problems? The Bergen district nursing home (BEDNURS) study. Qual Saf Health Care. 2003;12(3):176–80.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Davidsson M, Vibe OE, Ruths S, Blix HS. A multidisciplinary approach to improve drug therapy in nursing homes. J Multidiscip Healthc. 2011;4:9–13.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Thiruchelvam K, Hasan SS, Wong PS, Kairuz T. Residential aged care medication review to improve the quality of medication use: a systematic review. J Am Med Dir Assoc. 2017;18(1):87.e1–14.CrossRefGoogle Scholar
  34. 34.
    da Costa FA, Silvestre L, Periquito C, Carneiro C, Oliveira P, Fernandes AI, et al. Drug-related problems identified in a sample of portuguese institutionalised elderly patients and pharmacists’ interventions to improve safety and effectiveness of medicines. Drugs Real World Outcomes. 2016;3:89–97.CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Gallagher J, O’Sullivan D, McCarthy S, Gillespie P, Woods N, O’Mahony D, et al. Structured pharmacist review of medication in older hospitalised patients: a cost-effectiveness analysis. Drugs Aging. 2016;33(4):285–94.CrossRefPubMedGoogle Scholar
  36. 36.
    Chen TF. Pharmacist-led home medicines review and residential medication management review: the Australian model. Drugs Aging. 2016;33(3):199–204.CrossRefPubMedGoogle Scholar
  37. 37.
    Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug-related problems identification in general internal medicine: the impact and role of the clinical pharmacist and pharmacologist. Eur J Int Med. 2015;26(6):399–406.CrossRefGoogle Scholar
  38. 38.
    Delgado Silveira E, Fernandez-Villalba EM, Garcia-Mina Freire M, Albinana Perez MS, Casajus Lagranja MP, Peris Marti JF. The impact of pharmacy intervention on the treatment of elderly multi-pathological patients. Farm Hosp. 2015;39(4):192–202.PubMedGoogle Scholar
  39. 39.
    Lee J, McPherson ML. Outcomes of recommendations by hospice pharmacists. Am J Health Syst Pharm. 2006;63(22):2235–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Ollero M, Álvarez M, Barón B. Integrated care process [Pluripathological patients care]. 2nd ed. Andalucia: Andalucian Health Department; 2007.Google Scholar
  41. 41.
    Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.CrossRefPubMedGoogle Scholar
  42. 42.
    WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2013. WHO. 2012. http://www.whocc.no/filearchive/publications/1_2013guidelines.pdf. Accessed 23 Sept 2017.
  43. 43.
    Ong KY, Cheen MH, Chng JS, Chen LL, Ng SM, Lim SH, et al. Effectiveness of a multidisciplinary home-based medication review program in reducing healthcare utilization among older adult Singaporeans. Geriatr Gerontol Int. 2017;17(2):302–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Santos-Ramos B, Otero Lopez MJ, Galvan-Banqueri M, Alfaro-Lara ER, Vega-Coca MD, Nieto-Martin MD, et al. Health care models for patients with multiple chronic conditions and the role of the hospital pharmacy/the hospital pharmacist. Farm Hosp. 2012;36(6):506–17.PubMedGoogle Scholar
  45. 45.
    Spinewine A, Fialova D, Byrne S. The role of the pharmacist in optimizing pharmacotherapy in older people. Drugs Aging. 2012;29(6):495–510.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Pharmacy DepartmentDoctor Peset University HospitalValenciaSpain
  2. 2.Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)Doctor Peset University HospitalValenciaSpain
  3. 3.Comprehensive Medical UnitPare Jofre HospitalValenciaSpain

Personalised recommendations